Division of Infectious Diseases, Faculty of Medicine, The University of British Columbia, Vancouver, BC V6H 3Z6, Canada.
Int J Mol Sci. 2021 Aug 12;22(16):8661. doi: 10.3390/ijms22168661.
Lung cancer is the leading cause of cancer-related deaths in North America and other developed countries. One of the reasons lung cancer is at the top of the list is that it is often not diagnosed until the cancer is at an advanced stage. Thus, the earliest diagnosis of lung cancer is crucial, especially in screening high-risk populations, such as smokers, exposure to fumes, oil fields, toxic occupational places, etc. Based on the current knowledge, it looks that there is an urgent need to identify novel biomarkers. The current diagnosis of lung cancer includes different types of imaging complemented with pathological assessment of biopsies, but these techniques can still not detect early lung cancer developments. In this review, we described the advantages and disadvantages of current methods used in diagnosing lung cancer, and we provide an analysis of the potential use of body fluids as carriers of biomarkers as predictors of cancer development and progression.
肺癌是北美和其他发达国家癌症相关死亡的主要原因。肺癌位居榜首的原因之一是,通常在癌症处于晚期阶段才被诊断出来。因此,早期诊断肺癌至关重要,尤其是在筛查高危人群(如吸烟者、接触烟雾、油田、有毒职业场所等)时。根据目前的知识,似乎迫切需要识别新的生物标志物。目前肺癌的诊断包括不同类型的影像学检查,并辅以活检的病理评估,但这些技术仍然无法检测早期肺癌的发展。在这篇综述中,我们描述了当前用于诊断肺癌的方法的优缺点,并分析了体液作为生物标志物载体在预测癌症发展和进展方面的潜在用途。